OnKure Therapeutics is focused on developing precision medicines for cancer treatment, particularly through the exploration of targeted therapies that address specific genetic mutations. One of their key technologies involves the development of OKI-219, an allosteric, direct-mutation inhibitor specifically designed to target the PI3Kα H1047R mutation, which is prevalent in breast cancer and associated with drug resistance. This innovative approach aims to achieve high mutation-selectivity, allowing for enhanced efficacy while minimizing on-target toxicity that often limits the use of existing therapies. Preclinical studies have demonstrated that OKI-219 exhibits strong activity at low doses, both as a standalone treatment and in combination with other therapies, while also showing favorable safety profiles and the ability to penetrate the central nervous system.

In addition to OKI-219, OnKure is actively expanding its pipeline with other selective inhibitors targeting various mutations of the PI3Kα gene, including E542K and E545K. The company emphasizes the importance of leveraging its expertise in kinase inhibition and related biological pathways to identify and validate new oncology targets. By focusing on biologically validated drivers of cancer and ensuring a clear path for clinical proof of concept, OnKure aims to develop best-in-class drug candidates that can significantly improve treatment outcomes for patients with advanced solid tumors. Their ongoing clinical trials, such as the PIKture-01 trial for OKI-219, reflect their commitment to advancing these promising therapies in the oncology landscape.

United States

OnKure Therapeutics is a precision oncology company committed to the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancer.

OnKure Therapeutics

Company Details